MSD (tradename of Merck & Co., Inc., Rahway, N.J., USA), and Mayo Clinic, the world’s top-ranked hospital system, announced a research and development agreement to apply artificial intelligence (AI), advanced analytics and multimodal clinical data to support drug discovery and development. The agreement integrates Mayo Clinic’s Platform architecture as well as clinical and genomic datasets with MSD’s ambition to harness AI-enabled virtual cell technologies to enhance disease understanding, improve target identification and drive early development decisions.
